NAD+
NAD+ Original price was: $160.00.Current price is: $112.00.
Back to products
Melanotan-2 (MT-II)
Melanotan-2 (MT-II) Original price was: $45.00.Current price is: $31.50.

MOTS-C

Original price was: $50.00.Current price is: $35.00.

Buy high-purity MOTS-C for research. Third-party lab tested for purity, identity, and heavy metals.

Logistics & Guarantees

  • Shipping:ย Free 2-day US shipping over $120

  • Returns:ย 30-day returns

Technical Specsย 

  • Verified Purity:ย 99%+

  • Peptide Quantity: 10mg
  • Format: White lyophilized powder

  • Testing:ย Third-party tested, COAs available by batch
Description

Product details

Amino Acid Sequence

Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg

Molecular Formula

Cโ‚โ‚€โ‚Hโ‚โ‚…โ‚‚Nโ‚‚โ‚ˆOโ‚‚โ‚‚Sโ‚‚

Molecular Weight

2174.6 g/mol

PubChem CID

146675088

CAS Number

1627580-64-6

Vial Size

3ml

Contents

Lyophilized powder, white/off-white color

Mechanism of action

AMPK Activation

MOTS-C increases levels of AICAR and stimulates AMPK, leading to enhanced glucose uptake and fatty-acid oxidation.

Insulin Sensitivity

Improves glucose tolerance and insulin action in diet-induced obese mice; correlates with insulin signaling enhancement in skeletal muscle.

Exercise Mimetic Role

Circulating MOTS-C rises in humans during acute exercise; in mice, administration increases exercise performance and stress adaptation.

Cytoprotection

Acts as a โ€œmitokine,โ€ transmitting mitochondrial stress signals and promoting cellular resilience.

Storage & handling

Storage:

Store the lyophilized vial in a cool, dry area protected from direct sunlight.
Legal Disclaimer

All products on this site are for research and development, laboratory, or analytical use only; they are not for human consumption, medical, diagnostic, cosmetic, veterinary, or any other non-research application. The statements and products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Honest Peptide is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, nor an outsourcing facility as defined under section 503B.